TME Pharma N.V. · EURONEXT:ALTME
TME Pharma — Shareholder Meeting (June 2024)
36 slides from TME Pharma's shareholder meeting presentation, Jun 27, 2024
Slide 1: Annual General Meeting of Shareholders
www.tmepharma.com Annual General Meeting of Shareholders 27 June 2024
Slide 2: Agenda
AGENDA 1. Opening 2. Annual Accounts 2023 a. Discussion of the annual report 2023 (discussion) b. Policy on additions to reserves and on dividends (discussion) Voting results: all c. Adoption of the annual accounts 2023 (voting) unanimously approved d. Release from liability of the sole member of th
Slide 3: Agenda
AGENDA 4. Appointment of Baker Tilly (Netherlands) N.V. as statutory auditor for the financial year 2024 (voting) Voting results: unanimously approved 5. Partial amendment of the articles of association in relation to the increase of the authorised share capital (voting) Voting results: unanimously
Slide 4: Agenda Item 2a: Discussion of the annual report 2023
AGENDA ITEM 2a. Discussion of the annual report 2023 (discussion) 4
Slide 5: Pipeline Assets Complement Anti-Cancer Therapies to Enhance Treatment Efficacy
Pipeline Assets Complement Anti-Cancer Therapies to Enhance Treatment Efficacy Next Inflection Partner/ Therapy & Indication Preclinical Phase 1/2 Phase 2 Phase 3 Point Collaborator Protocol approved NOX-A12 + Radiotherapy ± anti-VEGF & Fast Track Financing and Brain cancer / Glioblastoma initiation
Slide 6: Highlights 2023 & Subsequent Events
AGENDA ITEM 2a. HIGHLIGHTS 2023 & Subsequent Events GLORIA NOX-A12 Phase 1/2 Study in First Line Brain Cancer Patients TME Pharma advanced its lead clinical program GLORIA, a Phase 1/2 study of NOX-A12 in first-line brain cancer (glioblastoma) patients in combination with radiotherapy ± anti-VEGF, b
Slide 7: NOX-A12 + anti-VEGF + RT: Improves median Overall Survival vs Standard of Care
NOX-A12 + anti-VEGF + RT: Improves median Overall Survival vs Standard of Care Reference Cohort mOS • Median overall survival (mOS): 19.9 months 19.9 months for NOX-A12 combo vs. 10.5 months for Standard of Care • 2 out of 6 patients survived longer than >24 months mOS • 50% overall survival at 21 m
Slide 8: Potential Predictive Biomarker: the EG12 Score
Potential Predictive Biomarker in Patient Treated with NOX-A12 + RT: the EG12 Score – published in Nature Communications • A predictive biomarker is a measurable biological characteristic that provides information about the likelihood of an individual patient to respond to a specific treatment • Ana
Slide 9: Highlights 2023: Pancreatic Cancer OPTIMUS Phase 2
AGENDA ITEM 2a. HIGHLIGHTS 2023 & Subsequent Events ▪ Pancreatic Cancer – OPTIMUS Phase 2 in combination with Keytruda® • As a result of the encouraging safety, tolerability and overall survival data obtained in the OPERA Phase 1/2 clinical trial, a Phase 2 trial in collaboration with MSD (European
Slide 10: Highlights 2023: Elimination of convertible debt vehicle
AGENDA ITEM 2a. HIGHLIGHTS 2023 & Subsequent Events Capital Structure – Elimination of convertible debt vehicle and all outstanding convertible bonds ▪ Termination of the convertible bond agreement with ASO in April 2023 other than with regard to the convertible bonds then held by ASO1 ▪ Redemption
Slide 11: Highlights 2023: Consolidated financial statements
AGENDA ITEM 2a. HIGHLIGHTS 2023 ▪ Consolidated financial statements 2023 - Cash and cash equivalents on balance sheet date of € 2.2 million (prior year: € 4.6 million) - Net loss of € 6.7 million (compared to € 15.1 million in 2022), with loss from operations of € 5.6 million (prior year: € 12.0 mil
Slide 12: Highlights 2023: Cash Position on December 31, 2023
AGENDA ITEM 2a. HIGHLIGHTS 2023 ▪ Cash Position on December 31, 2023 - On December 31, 2023, TME Pharma had cash resources of €2.2 million. - The Company successfully raised €4.8 million in cash in 2023 through the April 2023 financing transaction of € 2.0 million that involved € 1.0 million in equi
Slide 13: Consolidated Statements of Comprehensive Loss
AGENDA ITEM 2a. Consolidated Statements of Comprehensive Loss Remarks • Research and development expenses decreased 67% from K€ 8,148 in Financial (in K€) 2023 2022 Year (FY) 2022 to K€ 2,652 in FY 2023. The decrease is primarily driven by: Other operating income 17 34 • the clinical trial of NOX-A1
Slide 14: Consolidated Statements of Financial Position
AGENDA ITEM 2a. Consolidated Statements of Financial Position Remarks • The movements in total current assets from 31 December 2022 to 31 December (in K€) 2023 2022 2023 primarily relate to a decrease in cash and cash equivalents by K€ 2,389 from K€ Intangible assets 4 4 4,634 to K€ 2,245 as a resul
Slide 15: Consolidated Cash-Flow Statements
AGENDA ITEM 2a. Consolidated Cash-Flow Statements Remarks • The decrease in net cash used in operating activities from K€ 12,143 in FY 2022 to K€ 5,635 in FY 2023 was mainly a result of the decrease of the loss (in K€ ) 2023 2022 from operations from K€ 12,029 in FY 2022 to K€ 5,615 in FY 2023, part
Slide 16: Highlights 2023: Company only financial statements
AGENDA ITEM 2a. HIGHLIGHTS 2023 ▪ Company only financial statements 2023 - Cash at bank and in hand on balance sheet date of € 1.6 million (prior year: € 2.7 million) - Net result being a loss of € 6.7 million (compared to € 15.1 million in 2022), with - Loss from share in results from participating
Slide 17: Highlights 2023: ASO financing vehicle impact on equity
AGENDA ITEM 2a. HIGHLIGHTS 2023 ▪ ASO financing vehicle – impact on equity position of the Company - In the financial year ended 31 December 2023, 1,341 convertible bonds were issued (as compared to 8,138 convertible bonds issued in the financial year ended 31 December 2022), totaling drawn tranches
Slide 18: Balance Sheet of the Company
AGENDA ITEM 2a. • Balance Sheet of the Company Remarks • The Company’s total fixed assets include office equipment, right-of-use 31 Dec. 2023 31 Dec. 2022, 1 Jan. 2022, assets and financial fixed assets. Total fixed assets decreased from K€ 3,073 (in K€) restated * restated * as of 31 December 2022
Slide 19: Equity position of the Company
AGENDA ITEM 2a. • Equity position of the Company Remarks • As of 31 December 2023, the issued capital of the Company amounts to K€ 173 (prior year: K€ 1,739) and is (in K€ ) 2023 2022 divided into 17,320,845 ordinary shares (prior year: 1,739,335), each with a nominal value of € 0.01 (prior year Iss
Slide 20: Strong Value Proposition Through Differentiated Pipeline Targeting the Tumor Microenvironment
Strong Value Proposition Through Differentiated Pipeline Targeting the Tumor Microenvironment NOX-A12 VERY FOCUS ON UPCOMING MISSION LEVERAGEABLE PROMISING ORPHAN CANCER CATALYSTS TECHNOLOGY DATA INDICATIONS Brain Cancer (1st line GBM) Develop novel therapies Dual MoA leverageable Phase 1/2 clinical
Slide 21: Agenda Item 2b: Policy on additions to reserves and on dividends
AGENDA ITEM 2b. Policy on additions to reserves and on dividends (discussion) 21
Slide 22: Agenda Item 2c: Adoption of the annual accounts 2023
AGENDA ITEM 2c. Adoption of the annual accounts 2023 (voting) 22
Slide 23: Agenda Item 2d: Release from liability of the board of directors
AGENDA ITEM 2d. Release from liability of the sole member of the board of directors (voting) 23
Slide 24: Agenda Item 2e: Release from liability of the supervisory board
AGENDA ITEM 2e. Release from liability of the members of the supervisory board (voting) 24
Slide 25: Agenda Item 2f: Compliance with Dutch Corporate Governance Code 2022
AGENDA ITEM 2f. Compliance with the revised Dutch Corporate Governance Code 2022 (discussion) 25
Slide 26: Agenda Item 3a: Re-appointment of Dr. Maurizio PetitBon
AGENDA ITEM 3 a Re-appointment of Dr. Maurizio PetitBon as member of the supervisory board (voting) 26
Slide 27: Agenda Item 3b: Re-appointment of Dr. Cornelis Alexander Izeboud
AGENDA ITEM 3 b Re-appointment of Dr. Cornelis Alexander Izeboud as member of the supervisory board (voting) 27
Slide 28: Agenda Item 3c: Appointment of Dr. Lee Schalop
AGENDA ITEM 3 c Appointment of Dr. Lee Schalop as member of the supervisory board (voting) 28
Slide 29: Agenda Item 4: Appointment of statutory auditor
AGENDA ITEM 4 Appointment of Baker Tilly (Netherlands) N.V. as statutory auditor for the financial year 2023 (voting) 29
Slide 30: Agenda Item 5: Amendment of articles, authorised share capital
AGENDA ITEM 5 Partial amendment of the articles of association in relation to the increase of the authorised share capital (voting) 30
Slide 31: Agenda Item 6: Transitional provision for authorised share capital
AGENDA ITEM 6 Partial amendment of the articles of association in relation to re-instating a transitional provision to further increase the authorised share capital (voting) 31
Slide 32: Agenda Item 7: Delegation to issue shares
AGENDA ITEM 7 Renewal of the delegation to the board of directors to issue ordinary shares and/or preference shares and to limit or exclude any pre-emptive rights in connection therewith (voting) 32
Slide 33: Agenda Item 8: Delegation to acquire shares
AGENDA ITEM 8 Renewal of the delegation to the board of directors to acquire shares (voting) 33
Slide 34: Agenda Item 9: Amendment of remuneration policy
AGENDA ITEM 9 Amendment of the remuneration policy regarding the compensation structure of managing and supervisory board directors in addition to general amendments (voting) 34
Slide 35: Agenda Item 10: Close of Meeting
AGENDA ITEM 10 CLOSE OF MEETING 35
Slide 36: Thank You!
Thank You!